SI2771022T1 - CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe - Google Patents
CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabeInfo
- Publication number
- SI2771022T1 SI2771022T1 SI201231843T SI201231843T SI2771022T1 SI 2771022 T1 SI2771022 T1 SI 2771022T1 SI 201231843 T SI201231843 T SI 201231843T SI 201231843 T SI201231843 T SI 201231843T SI 2771022 T1 SI2771022 T1 SI 2771022T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cd40l
- methods
- specific
- derived scaffolds
- scaffolds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/80—Data visualisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Crystallography & Structural Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546028P | 2011-10-11 | 2011-10-11 | |
| PCT/US2012/059477 WO2013055745A2 (en) | 2011-10-11 | 2012-10-10 | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| EP12840074.4A EP2771022B1 (en) | 2011-10-11 | 2012-10-10 | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2771022T1 true SI2771022T1 (sl) | 2020-12-31 |
Family
ID=48082729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231843T SI2771022T1 (sl) | 2011-10-11 | 2012-10-10 | CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe |
Country Status (22)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008318357B2 (en) * | 2007-11-01 | 2015-01-22 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| DK2771022T3 (da) | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| PL3218406T5 (pl) | 2014-11-10 | 2025-01-27 | Medimmune Limited | Cząsteczki wiążące specyficzne dla CD73 i ich zastosowania |
| EP3842451A1 (en) * | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
| MA45573A (fr) | 2015-08-05 | 2019-05-15 | Janssen Biotech Inc | Anticorps anti-cd154 et procédés d'utilisation correspondant |
| EP3565847A1 (en) * | 2017-01-09 | 2019-11-13 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| WO2019108541A1 (en) * | 2017-11-28 | 2019-06-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant rsv g proteins and their use |
| WO2020068723A1 (en) * | 2018-09-24 | 2020-04-02 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| MX2021003514A (es) * | 2018-09-26 | 2021-05-27 | Viela Bio Inc | Antagonista del ligando del grupo de diferenciacion 40 (cd40l) y usos del mismo. |
| WO2020086885A2 (en) * | 2018-10-24 | 2020-04-30 | Brandeis University | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family pgt128 |
| KR102713267B1 (ko) | 2018-12-28 | 2024-10-04 | 스팍스 테라퓨틱스 인크. | 암 및 다른 질환을 치료하기 위한 클라우딘 18.2에 특이적인 결합 분자, 이의 조성물 및 방법 |
| CN111440253B (zh) * | 2019-01-17 | 2021-08-27 | 中国科学院上海药物研究所 | 立方形环糊精骨架-rgd组合物及其制备方法 |
| CA3219742A1 (en) * | 2021-05-21 | 2022-11-24 | Gabor Illei | Cd40l antagonist and uses thereof in the treatment of lupus nephritis |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024222895A1 (zh) | 2023-04-28 | 2024-10-31 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| WO1991015581A1 (en) | 1990-04-05 | 1991-10-17 | Roberto Crea | Walk-through mutagenesis |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5440018A (en) | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| EP0749475A4 (en) | 1992-08-26 | 1997-05-07 | Harvard College | USE OF CYTOKINE IP-10 AS ANTI-TUMOR AGENT |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| WO1996008513A1 (en) | 1994-09-16 | 1996-03-21 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| HUP0100813A3 (en) | 1998-02-25 | 2003-08-28 | Lexigen Pharmaceuticals Corp L | Enhancing the circulating half-life of antibody-based fusion proteins |
| AU731758B2 (en) | 1998-07-08 | 2001-04-05 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| HK1039355B (en) | 1998-12-02 | 2007-09-21 | Bristol-Myers Squibb Company | Dna-protein fusions and uses thereof |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK1137941T4 (da) | 1998-12-10 | 2014-01-06 | Brystol Myers Squibb Company | Protein-scaffolds til antistof-mimetika og andre bindingsproteiner |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1196637B1 (en) | 1999-07-27 | 2007-04-25 | Adnexus Therapeutics, Inc. | Peptide acceptor ligation methods |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US6951725B2 (en) | 2001-06-21 | 2005-10-04 | Compound Therapeutics, Inc. | In vitro protein interaction detection systems |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| WO2003083125A1 (en) | 2002-03-29 | 2003-10-09 | Genencor International, Inc. | Ehanced protein expression in bacillus |
| AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
| CA2489348A1 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
| KR100524872B1 (ko) | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| WO2006023144A2 (en) | 2004-07-06 | 2006-03-02 | Bioren Inc. | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
| KR100852415B1 (ko) | 2004-07-13 | 2008-08-18 | 재단법인서울대학교산학협력재단 | 인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체 |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| US8303955B2 (en) * | 2005-05-26 | 2012-11-06 | Seattle Genetics, Inc. | Humanized anti-CD40 antibodies and their methods of use |
| JP4959226B2 (ja) | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| CN104825433A (zh) | 2007-07-03 | 2015-08-12 | 达努塔·克鲁谢夫斯卡 | α-酮戊二酸的新医药用途 |
| JP5781762B2 (ja) * | 2007-08-10 | 2015-09-24 | プロテリックス、インク | ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| MX2010004374A (es) * | 2007-10-31 | 2010-04-30 | Medimmune Llc | Armazones proteinicos. |
| KR20100111283A (ko) * | 2007-12-27 | 2010-10-14 | 노파르티스 아게 | 개선된 피브로넥틴계 결합 분자 및 그들의 용도 |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| CN110317272A (zh) * | 2008-10-14 | 2019-10-11 | 霍夫曼-拉罗奇有限公司 | 免疫球蛋白变体及其用途 |
| WO2010051274A2 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| DK2427486T3 (en) | 2009-05-07 | 2015-05-26 | Novozymes Biopharma Dk As | A process for purifying albumin |
| WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| CN102741280B (zh) | 2009-10-30 | 2015-12-02 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| US8697650B2 (en) | 2010-02-16 | 2014-04-15 | Medimmune, Llc | HSA-related compositions and methods of use |
| ES2755398T3 (es) * | 2010-04-13 | 2020-04-22 | Medimmune Llc | Andamios multiméricos específicos de TRAIL R2 |
| EP4116325A1 (en) | 2010-11-05 | 2023-01-11 | Novartis AG | Methods of treating rheumatoid arthritis using il-17 antagonists |
| JP2014177354A (ja) | 2011-07-05 | 2014-09-25 | Asahi Glass Co Ltd | 窓ガラス |
| DK2771022T3 (da) | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
| MX2015005363A (es) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
| US20170260276A1 (en) | 2014-05-19 | 2017-09-14 | Medimmune Limited | Treatment for rheumatoid arthritis |
| EP3842451A1 (en) | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| MX2021003514A (es) | 2018-09-26 | 2021-05-27 | Viela Bio Inc | Antagonista del ligando del grupo de diferenciacion 40 (cd40l) y usos del mismo. |
-
2012
- 2012-10-10 DK DK12840074.4T patent/DK2771022T3/da active
- 2012-10-10 RS RS20201146A patent/RS60828B1/sr unknown
- 2012-10-10 WO PCT/US2012/059477 patent/WO2013055745A2/en not_active Ceased
- 2012-10-10 CN CN201810653215.1A patent/CN108948196B/zh active Active
- 2012-10-10 MX MX2014004065A patent/MX367013B/es active IP Right Grant
- 2012-10-10 AU AU2012323316A patent/AU2012323316B2/en active Active
- 2012-10-10 SG SG10201707813YA patent/SG10201707813YA/en unknown
- 2012-10-10 SM SM20200513T patent/SMT202000513T1/it unknown
- 2012-10-10 SI SI201231843T patent/SI2771022T1/sl unknown
- 2012-10-10 BR BR112014008804A patent/BR112014008804A2/pt not_active Application Discontinuation
- 2012-10-10 HU HUE12840074A patent/HUE051439T2/hu unknown
- 2012-10-10 KR KR1020207019515A patent/KR102434073B1/ko active Active
- 2012-10-10 US US14/347,016 patent/US10000553B2/en active Active
- 2012-10-10 HR HRP20201513TT patent/HRP20201513T1/hr unknown
- 2012-10-10 CA CA2851667A patent/CA2851667A1/en active Pending
- 2012-10-10 LT LTEP12840074.4T patent/LT2771022T/lt unknown
- 2012-10-10 PT PT128400744T patent/PT2771022T/pt unknown
- 2012-10-10 KR KR1020227028109A patent/KR20220116585A/ko not_active Ceased
- 2012-10-10 KR KR1020147012468A patent/KR102132997B1/ko active Active
- 2012-10-10 CN CN202211152182.5A patent/CN116063509A/zh active Pending
- 2012-10-10 JP JP2014535807A patent/JP6140712B2/ja active Active
- 2012-10-10 RU RU2014117511A patent/RU2704992C2/ru active
- 2012-10-10 EP EP20177799.2A patent/EP3753567A1/en active Pending
- 2012-10-10 CN CN201280049742.2A patent/CN103874501B/zh active Active
- 2012-10-10 KR KR1020247031456A patent/KR20240142616A/ko active Pending
- 2012-10-10 EP EP12840074.4A patent/EP2771022B1/en active Active
- 2012-10-10 SG SG11201400567QA patent/SG11201400567QA/en unknown
- 2012-10-10 ES ES12840074T patent/ES2819075T3/es active Active
-
2014
- 2014-04-03 MX MX2019009104A patent/MX2019009104A/es unknown
-
2017
- 2017-05-01 JP JP2017090963A patent/JP6539300B2/ja active Active
-
2018
- 2018-05-31 US US15/993,964 patent/US11104720B2/en active Active
-
2019
- 2019-06-07 JP JP2019106642A patent/JP7068231B2/ja active Active
-
2020
- 2020-10-02 CY CY20201100927T patent/CY1123690T1/el unknown
-
2021
- 2021-07-28 US US17/387,269 patent/US11555062B2/en active Active
-
2022
- 2022-04-28 JP JP2022073975A patent/JP7560507B2/ja active Active
- 2022-11-01 US US18/051,704 patent/US20230242619A1/en active Pending
-
2024
- 2024-09-19 JP JP2024161632A patent/JP2025000710A/ja active Pending
-
2025
- 2025-01-16 US US19/025,394 patent/US20250257120A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263020A (en) | New modulators and methods of use | |
| SG11201400567QA (en) | Cd40l-specific tn3-derived scaffolds and methods of use thereof | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| IL227440B (en) | Spherical support device and methods of use | |
| SG10201609940RA (en) | Compounds and their methods of use | |
| ZA201303793B (en) | Substituted quinoline compounds and methods of use | |
| ZA201209205B (en) | Pyridone and aza-pyridone compounds and methods of use | |
| PH12013501427A1 (en) | Melanin modification compositions and methods of use | |
| IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
| IL232977A0 (en) | Intra-episode dexmedetomidine preparations and methods of using them | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| IL215720A0 (en) | Dehumidifier and method of use thereof | |
| ZA201405829B (en) | Cleaning arrangement and method of use | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| GB2493595B (en) | Wheelchair and method of construction | |
| GB201102364D0 (en) | Lock means and method of use thereof | |
| HK1201463B (en) | Cd40l-specific tn3-derived scaffolds and methods of use thereof | |
| GB201101586D0 (en) | Lock means and method of use thereof | |
| GB201122402D0 (en) | Lock means and method of use thereof | |
| GB201014490D0 (en) | Cleaning means and method of use thereof |